CN101636399B - 可用作plk1抑制剂的取代的嘧啶并二氮杂* - Google Patents

可用作plk1抑制剂的取代的嘧啶并二氮杂* Download PDF

Info

Publication number
CN101636399B
CN101636399B CN2008800088890A CN200880008889A CN101636399B CN 101636399 B CN101636399 B CN 101636399B CN 2008800088890 A CN2008800088890 A CN 2008800088890A CN 200880008889 A CN200880008889 A CN 200880008889A CN 101636399 B CN101636399 B CN 101636399B
Authority
CN
China
Prior art keywords
methyl
mol
tetrahydro
pyrimido
diazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800088890A
Other languages
English (en)
Chinese (zh)
Other versions
CN101636399A (zh
Inventor
蔡建平
陈少清
崔信洁
乐康
建春·托马斯·陆
彼得·米夏埃尔·沃库利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101636399(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Takeda Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of CN101636399A publication Critical patent/CN101636399A/zh
Application granted granted Critical
Publication of CN101636399B publication Critical patent/CN101636399B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN2008800088890A 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂* Expired - Fee Related CN101636399B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210030872.3A Division CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Publications (2)

Publication Number Publication Date
CN101636399A CN101636399A (zh) 2010-01-27
CN101636399B true CN101636399B (zh) 2012-04-18

Family

ID=39415299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800088890A Expired - Fee Related CN101636399B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN201210030872.3A Expired - Fee Related CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210030872.3A Expired - Fee Related CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Country Status (23)

Country Link
US (1) US7517873B2 (cg-RX-API-DMAC7.html)
EP (1) EP2139892B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087640B2 (cg-RX-API-DMAC7.html)
KR (1) KR101157848B1 (cg-RX-API-DMAC7.html)
CN (2) CN101636399B (cg-RX-API-DMAC7.html)
AR (1) AR065794A1 (cg-RX-API-DMAC7.html)
AT (1) ATE524472T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008228303B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809088A2 (cg-RX-API-DMAC7.html)
CA (1) CA2680757A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000785A1 (cg-RX-API-DMAC7.html)
CY (1) CY1112102T1 (cg-RX-API-DMAC7.html)
DK (1) DK2139892T3 (cg-RX-API-DMAC7.html)
ES (1) ES2371832T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110807T1 (cg-RX-API-DMAC7.html)
IL (1) IL200617A (cg-RX-API-DMAC7.html)
MX (1) MX2009010034A (cg-RX-API-DMAC7.html)
PE (1) PE20120495A1 (cg-RX-API-DMAC7.html)
PL (1) PL2139892T3 (cg-RX-API-DMAC7.html)
PT (1) PT2139892E (cg-RX-API-DMAC7.html)
SI (1) SI2139892T1 (cg-RX-API-DMAC7.html)
TW (1) TWI363629B (cg-RX-API-DMAC7.html)
WO (1) WO2008113711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287339A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido [4, 5-b][1, 4] diazepin-2-ylamino)-3-methoxybenzamide Derivatives as Inhibitors of the Human Protein Kinases PLK1 to PLK4 for the Treatment of Proliferative Diseases
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
CN101878216B (zh) * 2007-09-28 2013-07-10 西克拉塞尔有限公司 作为蛋白激酶抑制剂的嘧啶衍生物
WO2009067547A1 (en) * 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEP20207129B (en) 2009-06-17 2020-07-10 Vertex Pharma Inhibitors of influenza viruses replication
WO2011031965A1 (en) 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
HUE038820T2 (hu) 2013-11-13 2018-11-28 Vertex Pharma Eljárás influenzavírusok replikációjának inhibitorai elõállítására
EP3099693A4 (en) * 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020356484A1 (en) 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
JP7555155B2 (ja) * 2021-08-10 2024-09-24 オップテラ インコーポレイテッド 新規plk1分解誘導化合物
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) * 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Also Published As

Publication number Publication date
CN102746175A (zh) 2012-10-24
AR065794A1 (es) 2009-07-01
HK1139936A1 (en) 2010-09-30
IL200617A (en) 2014-02-27
US7517873B2 (en) 2009-04-14
CL2008000785A1 (es) 2009-03-27
CA2680757A1 (en) 2008-09-25
AU2008228303B2 (en) 2012-04-19
TW200843781A (en) 2008-11-16
KR101157848B1 (ko) 2012-07-11
MX2009010034A (es) 2009-10-12
EP2139892A1 (en) 2010-01-06
HRP20110807T1 (hr) 2011-12-31
PE20120495A1 (es) 2012-05-12
PL2139892T3 (pl) 2012-03-30
BRPI0809088A2 (pt) 2014-09-09
TWI363629B (en) 2012-05-11
ATE524472T1 (de) 2011-09-15
EP2139892B1 (en) 2011-09-14
JP5087640B2 (ja) 2012-12-05
WO2008113711A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
PT2139892E (pt) 2011-11-21
CN101636399A (zh) 2010-01-27
JP2010521514A (ja) 2010-06-24
KR20090119913A (ko) 2009-11-20
US20080234255A1 (en) 2008-09-25
SI2139892T1 (sl) 2011-12-30
CN102746175B (zh) 2014-01-15
DK2139892T3 (da) 2011-12-12
CY1112102T1 (el) 2015-11-04
IL200617A0 (en) 2010-05-17
ES2371832T3 (es) 2012-01-10

Similar Documents

Publication Publication Date Title
CN102746175B (zh) 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN108697714B (zh) 稠合嘧啶化合物或其盐
CN104854101B (zh) Alk激酶抑制剂
RU2671494C2 (ru) Некоторые ингибиторы протеинкиназы
WO2020207260A1 (zh) 一种cdk激酶抑制剂及其应用
CN105121443B (zh) 蛋白激酶抑制剂
CN113874015B (zh) Ripk2的噻吩并吡啶抑制剂
CN107580597A (zh) Pi3k抑制剂的盐及其制备方法
EP3768272B1 (en) Jak inhibitors
KR20220006104A (ko) 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2022242697A1 (zh) Tyk2选择性抑制剂及其用途
WO2022160931A1 (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
KR20210131372A (ko) Syk 억제제로서의 축합된 피라진의 고체 형태
CN114981270B (zh) Mll1抑制剂和抗癌剂
CN110914273B (zh) 用于治疗糖尿病的作为pde1抑制剂的[1,2,4]三唑并衍生物
CN115650974B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
WO2024240256A1 (zh) 作为激酶抑制剂的多环化合物及其制备方法和用途
WO2026052129A1 (zh) 多环杂芳烃类glp-1受体激动剂
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
HK40003732B (en) Inhibitors of activin receptor-like kinase
HK1240216B (en) Certain protein kinase inhibitors
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED.

Free format text: FORMER OWNER: HOFFMAN-LALUOAI CO., LTD.

Effective date: 20100629

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: BASEL, SWITZERLAND TO: OSAKA, JAPAN

TA01 Transfer of patent application right

Effective date of registration: 20100629

Address after: Osaka

Applicant after: Takeda Chemical Industries, Ltd.

Address before: Basel

Applicant before: F. Hoffmann-La Roche AG

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120418

Termination date: 20150311

EXPY Termination of patent right or utility model